*Copyright permission pending - if interested in this measure, please contact us to discuss possible additional charges associated with this particular instrument
Additionally, as the technology partner of the International Consortium for Health Outcomes Measurement (ICHOM), OutcomeMD works to respect ICHOM’s recommended PROMs for colorectal cancer, breast cancer, localized prostate cancer, advanced prostate cancer and lung cancer when possible.
For conditions that encompass more than one patient area or domain (for example, lung cancer + pain intensity + fatigue), OutcomeMD has developed clusters of multiple PROs based on validated medical literature. With our PRO clusters, you will always have a comprehensive view of how your patient is progressing.
The value of OutcomeMD to Oncology:
- Improve your patients’ health and enhance the patient experience by engaging them in routine outcome tracking
- Use of patient reported outcome measures (PROs) to identify and treat patients with worsening symptoms led to improved overall survival (mean = 5 months) for individuals with metastatic cancer1
- In patients undergoing chemotherapy, the use of PROs increased communication with clinicians, improved satisfaction with emotional support from their clinician, and increased quality of life2
- Supplement your understanding of your patients’ health condition based on clinical markers, with real-time outcomes that are meaningful to your patients
- Compared to the self-reported pain, fatigue, nausea, dyspnea, and diarrhea outcomes of patients with advanced cancer, a significantly lower percentage of clinicians rated their patients’ symptoms as moderate or severe, supporting the importance of obtaining the patient perspective3
Did your patient have a great outcome? With OutcomeMD, your patients with good outcomes can now publicly celebrate their improvement with ease by posting on their social media accounts (lead generation) and on your review sites (reputation management)!
1Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 2017;318(2):197-8.
2Detmar SB, Muller MJ, Schornagel JH, Wever LDV, Aaronson NK. Health-related quality-of life assessments and patient-physician communication: a randomized controlled trial. JAMA 2002;288(23):3027-34.
3Laugsand EA, Sprangers MA, Bjordal K, Skorpen F, Kaasa S, Klepstad P. Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes 2010;8:104.
